Skip to main content
Contact Us
Subscribe
E-Edition
88°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by VALNEVA
< Previous
1
2
Next >
Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, IXCHIQ®
November 10, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates
November 09, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference
November 07, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment
October 25, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva to Present on Chikungunya at Several Leading Scientific Conferences
October 11, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 Million
September 25, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
September 21, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
September 07, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva to Participate in Investor Conferences in the United States and Europe in September 2023
August 31, 2023
From
VALNEVA
Via
GlobeNewswire
Health Canada Accepts Valneva’s Chikungunya Vaccine License Application for Review
August 29, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate
August 28, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Announces Extension of Existing Loan Agreement
August 17, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Announces PDUFA Date Extension for Chikungunya Virus Vaccine Candidate
August 14, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Supervisory Board Recommends Transition from a Two-Tier Governance Model to a Board of Directors
June 22, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Announces Successful Outcome of its AGM and the Appointment of Pfizer’s Former Vaccine R&D Head to its Supervisory Board
June 21, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in The Lancet
June 13, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June
May 31, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Announces the Availability of Documentation for its Shareholder Meeting
May 31, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Files for Chikungunya Vaccine Authorization with Health Canada
May 30, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Reports First Quarter 2023 Financial Results and Provides Corporate Updates
May 04, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Announces Filing of 2022 Universal Registration Document and US Form 20-F
March 31, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva to Present on its Chikungunya Vaccine Candidate and Host a Roundtable at the 23rd World Vaccine Congress in Washington D.C.
March 30, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Full Year 2022 Results and Provides Corporate Updates
March 23, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001
March 02, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva to Present at the Cowen 43rd Annual Healthcare Conference
March 01, 2023
From
VALNEVA
Via
GlobeNewswire
FDA Accepts Valneva’s Chikungunya Vaccine License Application for Priority Review
February 20, 2023
From
VALNEVA
Via
GlobeNewswire
Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15
February 17, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Full Year 2022 Revenue and Cash, Provides First 2023 Guidance
February 16, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate
February 14, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine
December 30, 2022
From
VALNEVA
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.